Clinical trials: P-cresol

Inflammatory Status, P-cresol

HFR Cartridge and Inflammation

• Completed
• Age: 18 to 70 years
• Surgery or procedure

A major limitation of standard hemodialysis is that it does not clear the plasma from interleukin-6 (IL-6) and p-cresol, two uremic toxins responsible for the high cardiovascular risk in end stage renal disease (ESRD).

Trial name

HFR (NCT01865773)

Testing

HFR dialysis

Where

Italy

Volunteers

8 people, healthy volunteers welcome

Sponsor

Federico II University